13686-41-4

Basic information

• Product Name: 2,2-dimethyl-3-phenyl-3-butenoic acid
• Synonyms: 2,2-dimethyl-3-phenyl-3-butenoic acid
• CAS NO: 13686-41-4
• Molecular Weight: 190.242
• Mol File: 13686-41-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2,2-dimethyl-3-phenyl-3-butenoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-dimethyl-3-phenyl-3-butenoic acid(13686-41-4)
• EPA Substance Registry System: 2,2-dimethyl-3-phenyl-3-butenoic acid(13686-41-4)

Safety Data

• Hazardous Substances Data: 13686-41-4(Hazardous Substances Data)

Upstream product

• 25491-42-3 ethyl 2,2-dimethyl-3-oxo-3-phenylpropionate 
• 72012-45-4 ethyl 2,2-dimethyl-3-phenyl-3-butenoate 

Downstream Products

• 107203-43-0 2-methyl-3-phenylbut-3-en-2-yl acetate 
• 859810-79-0 3,3-dimethyl-4-phenylfuran-2(3H)-one 
• 25982-72-3 2-methyl-3-phenyl-but-3-en-2-ol 
• 18476-73-8 (3-methylbuta-1,3-dien-2-yl)benzene 
• 108475-84-9 (+/-)-4-methyl-5-phenyl-cyclohex-4-ene-1r,2c-dicarboxylic acid-anhydride 
• 76803-38-8 1-Diazo-3,3-dimethyl-4-phenyl-pent-4-en-2-one 
• 76803-47-9 2,2-dimethyl-3-phenyl-3-cyclopentenone 
• 124-38-9 carbon dioxide 
• 769-57-3 α,β,β-trimethylstyrene 
• 17498-71-4 3-methyl-2-phenyl-1-butene 

Relevant articles and documents

Domino Aryne Annulation via a Nucleophilic-Ene Process

1,2-Benzdiyne equivalents possess the unique property that they can react with two arynophiles through iteratively generated 1,2- and 2,3-aryne intermediates. Upon rational modification on the second leaving group of these aryne precursors, a domino aryne annulation approach was developed through a nucleophilic-ene reaction sequence. Various benzo-fused N-heterocyclic frameworks were achievable under transition metal-free conditions with a broad substrate scope.

TRIAZOLE DERIVATIVE OR SALT THEREOF

[Problem] There is provided a compound which can be used for therapy of diseases in which 11 β-hydroxysteroid dehydrogenase type 1(11β-HSD1) participates, in particular diabetes, insulin resistance. [Means for Solution] It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11β-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action and hence can be used for therapy of diabetes, insulin resistance.